Document and Entity Information Statement [Table] Statement [Line Items] Statement Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] ASSETS Assets, Current [Abstract] Current Assets: Cash Cash at end of period Cash at beginning of period Cash Prepaid Expense, Current Prepaid expenses Assets, Current Total Current Assets Property, Plant and Equipment, Net Property and equipment, net Indefinite-Lived Intangible Assets (Excluding Goodwill) In-process research and development Goodwill Ending balance Beginning balance Goodwill Other Assets Other assets Assets Total Assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current Liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total accrued expenses Capital Lease Obligations, Current Capital lease liability Liabilities, Current Total Current Liabilities Business Combination, Contingent Consideration, Liability, Noncurrent Contingent consideration Contingent consideration Deferred Tax Liabilities, Net, Noncurrent Deferred tax liability Derivative Liability, Noncurrent Derivative financial instruments, at estimated fair value - warrants Derivative financial instruments liability - warrants Liabilities Total Liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholder's Equity: Preferred Stock, Value, Issued Convertible preferred stock Common Stock, Value, Issued Common stock, par value of $.0001 per share. Authorized 120,000,000 shares, 63,707,348 and 32,231,241 shares issued and outstanding at March 31, 2017 and June 30, 2016, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total Stockholders' Equity Liabilities and Equity Total Liabilities and Stockholders' Equity Preferred Stock, Par or Stated Value Per Share Convertible preferred stock, par/stated value (in dollars per share) Convertible preferred stock, stated value (in dollars per share) Preferred Stock, Shares Authorized Convertible preferred stock, shares authorized Preferred Stock, Shares Issued Convertible preferred stock, shares issued Preferred Stock, Shares Outstanding Convertible preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Costs and Expenses [Abstract] Costs and Expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Income (Loss) Loss from Operations Amount of expense (income) related to adjustment to fair value of warrant liability and Contingent Consideration. Fair Value Adjustment Of Warrants and Contingent Consideration Change in fair value of derivative financial instruments-warrants and contingent consideration Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before income taxes Income Tax Expense (Benefit) Income tax benefit Net Income (Loss) Attributable to Parent Net loss Net loss Net loss Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted Average Common Shares Outstanding Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and Diluted (in shares) Weighted average common shares outstanding (in shares) Earnings Per Share, Basic and Diluted [Abstract] Net Loss per Common Share Earnings Per Share, Basic and Diluted Basic and Diluted (in dollars per share) Net loss per share of common stock-basic and diluted (in dollars per share) CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid in Capital Retained Earnings [Member] Accumulated Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares, Outstanding Balance (in shares) Balance (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock, net Stock Issued During Period, Shares, New Issues Issuance of common stock, net (in shares) Sale of shares (in shares) Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of preferred stock to common stock Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of preferred stock to common stock (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock based compensation expense Value of warrants issued as a result of the exercise of warrants. Stock Issued During Period Value Warrants Exercised Exercise of warrants Number of warrants exercised during the current period. Stock Issued During Period Shares Warrants Exercised Exercise of warrants (in shares) Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Exercise of stock options (in shares) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash Flows From Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation Stock-based compensation expense Fair Value Adjustment of Warrants Change in fair value of derivative instrument-warrants Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Change in fair value of contingent consideration Depreciation, Depletion and Amortization Depreciation and amortization expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Cash used in Operating Activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash Flows From Investing Activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net Cash Used in Investing Activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash Flows From Financing Activities: The increase (decrease) during the reporting period in the value of Capital Lease. Payments made for capital lease Current portion of capital lease The cash inflow from the additional capital contribution to the entity and rights to purchase common shares at predetermined price (usually issued together with corporate debt). Proceeds from Issuance of Common Stock, and Warrants Proceeds from the issuance of common stock and warrants, net Proceeds from Warrant Exercises Proceeds from exercise of warrants Proceeds from Stock Options Exercised Proceeds from the exercise of stock options Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net Cash provided by Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase\(decrease) in cash Supplemental Cash Flow Information [Abstract] Supplementary Disclosure Of Non-Cash Financing Activities: Conversion of Stock, Amount Converted Conversion of convertible preferred stock Represents the fair value of warrants issued as on balance sheet date. Fair Value of Warrants Issued Fair value of warrants issued in conjunction with common stock offering No definition available. Business Overview The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. Also includes disclosure of issuance of stock. Nature of Operations and Stock Issuance [Text Block] Business Overview Basis of Presentation and Going Concern The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Also includes the entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. Basis Of Presentation And Substantial Doubt about Going Concern [Text Block] Basis of Presentation and Going Concern Recent Accounting Pronouncements New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Recent Accounting Pronouncements Business Combination Business Combination Disclosure [Text Block] Business Combination No definition available. Stockholder's Equity and Derivative Liability The entire disclosure for stockholder's equity (deficit) and derivative liability. Stockholders' Equity (Deficit) and Derivative Liability Disclosure [Text Block] Stockholder's Equity and Derivative Liability Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Indefinite-lived Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Indefinite-lived Intangible Assets and Goodwill Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Liabilities Accounting for Share-Based Payments Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Accounting for Share-Based Payments Loss per Share Earnings Per Share [Text Block] Loss per Share Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Income Tax Benefit Income Tax Disclosure [Text Block] Income Tax Benefit Basis of Accounting, Policy [Policy Text Block] Going Concern Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Derivatives, Policy [Policy Text Block] Derivative financial instruments Research and Development Expense, Policy [Policy Text Block] Research and Development Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-based payments Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of acquisition-date fair value of consideration transferred Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Summary of estimated fair values of assets acquired and liabilities assumed Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Schedule of fair value of liabilities recognized at fair value on recurring basis Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. Also includes tabular disclosure of reconciliation of beginning and ending balances of financial instrument. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, and Financial Instrument Reconciliation [Table Text Block] Schedule of changes in derivative financial instruments liability balance Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of table represents the liabilities measured and recognized at fair value on a recurring basis Represents tabular information of changes in fair value of contingent consideration. Schedule Of Fair Value For Contingent Consideration Table Text Block Schedule of changes in fair value of contingent consideration Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Schedule of IPR&D asset Schedule of Goodwill [Table Text Block] Schedule of roll-forward of goodwill balance Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued liabilities Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock based compensation expense Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option activity and of changes in stock options outstanding under the Plan Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted-average assumptions used to estimate fair value of stock option awards granted to employees Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of basic and diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of outstanding securities excluded from the computation of diluted weighted shares outstanding Schedule reflecting the information pertaining to business overview. Business Overview [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Business Overview [Line Items] Business Overview Represents the number of wholly-owned subsidiary. Number of Wholly Owned Subsidiary Number of wholly-owned subsidiary Going Concern [Abstract] Going Concern Represents the working capital of the entity. Working Capital Working capital Represents the prepaid costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, charged to research and development projects. Prepaid Research and Development Expense Prepaid research and development costs Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Business Combination Business Acquisition, Percentage of Voting Interests Acquired Voting interest acquired (as a percent) Acquisition-date fair value of consideration transferred Acquisition-date fair value of consideration transferred Payments to Acquire Businesses, Gross Cash Amount of notes receivable settled upon closing of transaction under business combination arrangement. Business Combination, Consideration Transferred, Notes Receivable Settled Upon Closing Notes receivable settled upon closing of transaction Business Combination, Consideration Transferred Total consideration Debt Instrument, Face Amount Amount of debt Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Business Acquisition, Contingent Consideration [Line Items] Contingent Consideration Business Combination, Contingent Consideration Arrangements, Percentage of Issued and Outstanding Percentage of issued and outstanding common stock on the closing date under contingent consideration arrangement. ng Common Stock on Closing Date Business Combination, Contingent Consideration Arrangements, Percentage of Issued and Outstanding Common Stock on Closing Date Percentage of issued and outstanding common stock on closing date Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Milestone payment of contingent consideration Estimated preliminary fair values of assets acquired and liabilities assumed Estimated preliminary fair values of assets acquired and liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Cash Amount of tax receivables, acquired at the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tax Receivable Tax receivable Amount of asset related to consideration paid in advance for rent, acquired at the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Rent Prepaid rent Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Property, plant and equipment, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets In-process research and development Amount of current portion of capital lease obligation, assumed at the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Capital Lease Obligation Current portion of capital lease Amount of deferred tax liability attributable to taxable temporary differences, assumed at the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Total net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Total consideration Number of prior period adjustments to previously issued financial statements, including an adjustment that is a correction of an error. Number of measurement period adjustments Number of measurement period adjustments Schedule of Stock by Class [Table] Class of Stock [Line Items] Series A and Series B Convertible Preferred Stock Number of preferred shares issued in private placement during the period. Preferred Stock Issued during Period, Shares, Private Placement Shares issued (in shares) Proceeds from Issuance of Convertible Preferred Stock Gross proceeds from sale of stock The number of additional nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. Preferred Stock, Additional Shares Authorized Additional number of shares available for purchase by the underwriters Number of preferred stock issued as payment for license under terms of agreement. Preferred Stock Issued During Period, Shares, Issued for License Shares issued in connection with license (in shares) Value of preferred stock issued as payment for license under terms of agreement. Preferred Stock Issued During Period, Value, Issued for License Fair value of preferred stock issued Conversion of Stock, Shares Converted Shares converted, Preferred Stock Convertible Preferred Stock, Shares Issued upon Conversion Shares converted, Common Stock Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] n/a Common Stock and Warrant Offering [Abstract] Common Stock and Warrant Offering The number of shares offered for sale under the agreement. Underwriting Agreement, Shares Authorized Number of shares offered for sale The maximum number of shares that may purchased from warrants offered for sale. Underwriting Agreement, Warrants Authorized Maximum number of shares to be purchased from warrants offered for sale Price of a single unit of a number of saleable securities of a company (in dollars per unit). Each unit consists of a combination of the entity's common stock and warrants to purchase additional shares of the entity's common stock. Purchase Price Per Unit Purchase price (in dollars per unit) Period of time from date of issuance over which each class of warrants or rights outstanding my be exercised, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Class of Warrant or Right, Term Exercise period for warrants Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants (in dollars per share) Period of time over which the underwriter has option to purchase additional shares over the initial allotment, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Overallotment Option, Period Underwriter option period Proceeds received on stock transaction before deduction of issuance costs. Sale of Stock, Gross Consideration Received on Transaction Gross proceeds from sale of stock and warrants (in dollars) Payments of Stock Issuance Costs Underwriting discount and other offering expenses payable The expected cash inflow associated with the amount received from holders exercising their stock warrants, if the warrants are exercised in full. Proceeds From Warrant Exercises, If Exercised In Full Expected proceeds if warrants exercised in full Share Price Price of ContraVir common stock Stock price (in dollars per share) Fair Value Assumptions, Expected Term Expected warrant term (years) Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate (as a percent) Fair Value Assumptions, Weighted Average Volatility Rate Expected volatility (as a percent) Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Components of changes in derivative financial instruments liability Class of Warrant or Right, Outstanding Balance at end of period (in shares) Balance at the beginning of the period (in shares) Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs Balance at end of period Balance at the beginning of the period Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings Change in fair value of warrants The number of warrants or rights which the entity has issued. Class of Warrant or Right Issued Issuance of warrants (in shares) Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues Issuance of warrants Schedule of stock transactions. Schedule Of Stockholders' Equity, Stock Transactions [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Schedule Of Stockholders' Equity, Stock Transactions [Line Items] Controlled Equity Offering Sales Agreement Maximum aggregate share amount issuable under the agreement. Common Stock, Aggregate Maximum Issue Amount Under Agreement Maximum aggregate offering price Represents maximum selling agent fee expressed as a percentage of gross sales price per share sold. Commission Payable to Sales Agent as Percentage of Gross Sales Price Per Share Sold, Maximum Selling agent fee as a percentage of gross sales price per share sold Proceeds from Issuance of Common Stock Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value measurements Derivative Liability, Fair Value, Gross Liability Derivative liabilities related to Warrants Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Change in fair value of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Balance at end of the period Balance at beginning of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in fair value recorded in earnings Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Impairment losses on IPR&D Schedule of Goodwill [Table] Goodwill [Line Items] Goodwill Goodwill [Roll Forward] Roll-forward of goodwill balance Goodwill, Impairment Loss Impairment losses on goodwill Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Research and Development Expenses Current Research and development Accrued Professional Fees, Current Professional fees Employee-related Liabilities, Current Payroll and related costs Carrying value as of the balance sheet date of obligations incurred through that date and payable for legal fees, such as for legal services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Legal Fees Current Legal fees Other Accrued Liabilities, Current Other Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Equity Award [Domain] An arrangement whereby an employee or nonemployee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Employee And Nonemployee Stock Options [Member] Stock options Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] General And Administrative Expense [Member] General and administrative Research And Development Expense [Member] Research and development Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Accounting for Shared-Based Payments Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period for stock options granted under the plan Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Contractual term of stock options Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares of common stock initially reserved for issuance, pursuant to the Plan Share-based Compensation [Abstract] Stock based compensation expense Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees, net of expense reversals. Allocated Share Based Compensation Expense, Net Total stock based compensation expense An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Non Employee Stock Option [Member] Non-employee stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Balance outstanding at the end of the period (in shares) Balance outstanding at the beginning of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Number of options unvested out of total outstanding non employee options Share based Compensation Arrangement By Share based Payment Award Options Unvested Number Of Shares Number of options unvested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested awards and those expected to vest at the end of the period (in shares) No definition available. Share Based Compensation Arrangement by Share Based Payment Award, Options Exercise Price [Abstract] Exercise Price Per Share Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Exercise price, low end of the range (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Exercise price, high end of the range (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Balance outstanding at the end of the period (in dollars per share) Balance outstanding at the beginning of the period (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested awards and those expected to vest at the end of the period (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award Options Intrinsic Value [Abstract] Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Balance outstanding at the end of the period (in dollars) Balance outstanding at the beginning of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Remaining Contractual Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Balance outstanding at the end of the period No definition available. Share-based Compensation Arrangement by Share-based Payment, Additional Disclosures [Abstract] Share-based payments Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Total fair value of shares vested during the period Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract] Unrecognized compensation cost related to non-vested stock options outstanding Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation cost related to non-vested stock (in dollars) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Weighted average remaining vesting period over which unrecognized compensation is expected to be recognized Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Weighted-average assumptions to determine fair value of stock option awards Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Actual future unvested option forfeitures as a percent of options granted. Share Based Compensation Arrangement By Share Based Payment Award Actual Forfeitures Percentage Actual future unvested option forfeitures (as a percent) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Warrant [Member] Warrants Earnings Per Share Basic and Diluted [Line Items] Loss per Share No definition available. Earnings Per Share, Numerator [Abstract] Numerator: Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common stockholders No definition available. Earnings Per Share, Denominator [Abstract] Denominator: Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract] Securities excluded from the computation of diluted weighted shares outstanding Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities (in shares) Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Agreement Represents the maximum payments to be made upon the achievement of clinical, regulatory and initial commercial milestones under the terms of the agreement. Agreement Maximum Payments To Be Made Upon Achievement of Milestones Maximum payments to be made for clinical, regulatory and initial commercial milestones Minimum period for which entity must provide prior written notice in order to terminate agreement on a country by country basis, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement Minimum Written Notice Minimum prior written notice period in order to terminate agreement Represents the value of stock issued relating to the cost of the license classified as research and development expense during the period. Research and Development Expense, Cost of License Cost of license classified as research and development expense The amount accrued related to the payments, to be made under License agreement. Accrued Payments Related to License Agreement Amounts accrued related to the payments Stock Issued During Period, Shares, Purchase of Assets Shares issued for assets (in shares) Represents the percentage of outstanding shares of common stock upon issuance. Percentage Of Outstanding Shares Of Common Stock Upon Issuance Percentage of outstanding shares of common stock upon issuance Period for which counterparty must provide prior written notice in order to terminate agreement if entity breaches or defaults on obligations, subject to cure period, under the terms of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement, Written Notice Period, Counterparty Written notice period Period after written notice received from counterparty in which entity may cure default or breach of contract obligations in order to prevent termination of agreement under the terms of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement, Default Or Breach Cure Period, Entity Default or breach cure period Maximum period in which payment is considered to be late under the terms of the agreement. Agreement, Late Payment, Period Late payment period Number of occasions in twelve month period in which agreement may be terminated if entity is late on making payment under the terms of the agreement. Agreement, Late Payments, Number of Occasions Number of occasions in 12 month period Period for which entity must provide prior written notice in order to terminate agreement if patent(s) that are irrevocably adjudicated to be invalid exceed royalty threshold under the terms of the agreement, , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement, Written Notice Period One, Entity First written notice period Minimum threshold percentage of royalty from patents that are irrevocably adjudicated to be invalid under the terms of agreement. Agreement, Percentage of Royalty, Minimum Royalty threshold rate (as a percent) Period for which entity must provide prior written notice for breach related to confidential information and publication in order to terminate agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement, Written Notice Period Two, Entity Second written notice period Maximum period after written notice received from entity in which counterparty may cure default or breach of contract in order to prevent termination of agreement under the terms of the agreement, , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement, Default Or Breach Cure Period, Counterparty Counterparty's default or cure period Amount of initial base payment previously paid under the terms of the agreement. Agreement, Initial Base Payment Made Initial base payment made Aggregate amount of milestone payments that may be payable under the terms of the agreement. Agreement, Milestone Payment, Aggregate Amount Aggregate milestone payment Amount of milestone payment that may be payable upon initiation of a Phase 3 clinical trial for a licensed product under the terms of the agreement. Agreement, Milestone Payment, Phase Three Clinical Trial Milestone payment upon initiation of phase 3 clinical trial Amount of milestone payment that may be payable upon approval of first New Drug Application (NDA) for a licensed product under the terms of the agreement. Agreement, Milestone Payment, Approval of First New Drug Application Milestone payment upon approval of drug application Amount of initial base payment under the terms of agreement. Agreement, Initial Base Payment Initial base payment Amount of milestone payment that may be payable upon receiving marketing approval under terms of the agreement. Agreement, Milestone Payment, Marketing Approval Milestone payment upon receiving marketing approval Amount of milestone payment that may be payable upon achieving net sales threshold under the terms of the agreement. Agreement, Milestone Payment, Net Sales Threshold Milestone payment upon achieving net sales threshold Net sales threshold for achieving milestone under the terms of the agreement. Agreement, Milestone Payment, Net Sales Threshold Amount Net sales threshold amount Amount of cash outflow for milestone payments. Agreement, Milestone Payment Milestone payments Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Related Party Transactions Payments to Suppliers Payments for services Accounts Payable, Related Parties, Current Outstanding payables Represents the proceeds from participating in the New Jersey Technology Business Tax Certificate Transfer Program. NOL Certificate Transfer Proceeds from sale of net operating losses to third party Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Series A Preferred Stock [Member] Series A convertible preferred stock Series B Preferred Stock [Member] Series B convertible preferred stock Convertible Preferred Stock [Member] Convertible preferred stock Preferred Stock [Member] Preferred Stock Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Represents warrants issued at October 13th, 2015. October132015 [Member] October 13 2015 Represents warrants issued at April 4th, 2016. April42016 [Member] April 4 2016 Business Acquisition [Axis] Business Acquisition Acquiree [Domain] Business Acquisition, Acquiree [Domain] Represents the information pertaining to Ciclofilin Pharmaceuticals, Inc. Ciclofilin Pharmaceuticals Inc. [Member] Ciclofilin Short-term Debt, Type [Axis] Short Term Debt Type [Domain] Short-term Debt, Type [Domain] Convertible Notes Payable [Member] Convertible notes payable Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Represents the information pertaining to Upon receipt of Phase I Positive Data from the Phase I trial of CRV431 in humans. Upon Receipt Of Phase One Positive Data From Phase One Trial Of C R V431 In Humans [Member] Upon receipt of Phase I Positive Data from Phase I trial of CRV431 in humans Represents the information pertaining to Upon receipt of Phase II Positive Data from a proof of concept clinical trial (whether an HBV-positive Phase I clinical trial or a separate Phase II clinical trial, or otherwise) of CRV431 in humans. Upon Receipt Of Phase Two Positive Data From Proof Of Concept Clinical Trial Of C R V431 In Humans [Member] Upon receipt of Phase II Positive Data from proof of concept clinical trial of CRV431 in humans Represents the information pertaining to Upon initiation of a Phase III trial of CRV431. Upon Initiation Of Phase Three Trial Of C R V431 [Member] Upon initiation of Phase III trial of CRV431 Represents the information pertaining to Upon the acceptance by the U.S. Food and Drug Administration of a new drug application for CRV431. Upon Acceptance By U S Food And Drug Administration Of New Drug Application C R V431 [Member] Upon acceptance by U.S. Food and Drug Administration of new drug application for CRV431 Counterparty Name [Axis] Repurchase Agreement Counterparty Name [Domain] Counterparty Name [Domain] Purchaser of the entity's shares of stock in a private offering. Purchaser [Member] Purchaser Information pertaining to Chimerix, Inc. Chimerix Inc [Member] Chimerix, Inc. Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements And Nonarrangement Transactions [Member] Arrangements and Non-arrangement Transactions [Domain] Represents information pertaining to a license agreement. License Agreement [Member] License Agreement Sale of Stock [Axis] Sale Of Stock Name Of Transaction [Domain] Sale of Stock [Domain] Underwriting agreement entered into by the entity in October 2015 to sell shares of common stock and warrants to purchase common stock under the entity's current shelf registration statement. Excludes information pertaining to overallotment option. Underwriting Agreement [Member] Underwriting agreement Overallotment option included in the underwriting agreement entered into by the entity in October 2015 in which the underwriters may purchase additional shares of common stock and warrants under the entity's current shelf registration statement. Underwriting Agreement Overallotment Option [Member] Underwriting agreement, overallotment option Security that gives the holder the right to purchase shares of common stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Common Stock Warrants [Member] Common stock warrants Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Information pertaining to sale of stock through a controlled equity offering sales agreement entered into on March 9, 2015 to sell securities through an agent. Controlled Equity Offering Sales Agreement March92015 [Member] Controlled Equity Offering Sales Agreement Measurement Frequency [Axis] Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements Recurring [Member] Recurring basis Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Inputs Level3 [Member] Significant Unobservable Inputs (Level3) Liability Class [Axis] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain] Fair Value by Liability Class [Domain] Represents Acquisition related contingent consideration. Contingent Consideration [Member] Acquisition related contingent consideration Indefinite-lived Intangible Assets [Axis] Indefinite Lived Intangible Assets Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] In Process Research And Development [Member] IPR&D Products and Services [Axis] Products And Services [Domain] Products and Services [Domain] Represents the information pertaining to CRV 431. C R V431 [Member] CRV431 Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Represents information pertaining to the Equity Incentive Plan. Equity Incentive Plan [Member] Equity Incentive Plan Employee Stock Option [Member] Stock options Exercise Price Range [Axis] Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Represents Exercise Price Range One. Exercise Price Range One [Member] Exercise Price Range $0.11-$4.38 Represents Exercise Price Range Two. Exercise Price Range Two [Member] Exercise Price Range $1.04-$2.01 Represents Exercise Price Range Three. Exercise Price Range Three [Member] Exercise Price Range $0.11-$2.35 Represents information pertaining to a contribution agreement. Contribution Agreement [Member] Contribution Agreement Information pertaining to University College Cardiff Consultants Limited. University College Cardiff Consultants Limited [Member] Cardiff Information pertaining to Bristol-Myers Squibb. Bristol Myers Squibb [Member] BMS Related Party [Axis] Related Party [Domain] Related Party [Domain] Affiliated Entity [Member] Affiliated Entity Principal Owner [Member] Gabriele Cerrone Represents information pertaining to consulting agreement for scientific and technical advisory services. Consulting Agreement [Member] Consulting agreement Represents the entity, Baruch S. Blumberg Institute. Baruch S Blumberg Institute [Member] Blumberg Institute Represents the entity, Clinical Supplies Management, Inc. Clinical Supplies Management Inc [Member] CSM